OKYO Pharma Limited’s SEC filings document foreign-private-issuer reports on Form 6-K for a clinical-stage biopharmaceutical company with ordinary shares listed on Nasdaq. The disclosures cover urcosimod clinical and regulatory updates for neuropathic corneal pain, scientific-meeting materials, and descriptions of the company’s focus on inflammatory eye diseases and other ocular disorders.
The filing record also includes capital-structure and financing disclosures tied to Form F-3 registration statements, ordinary-share offerings, underwriter option exercises, and insider share purchases. These records present formal updates on the company’s securities, ownership activity, incorporated exhibits, and material announcements furnished under Exchange Act Rule 13a-16.
OKYO Pharma Ltd director Simon Willy Jules has filed a Form 3 reporting his initial ownership in the company. He holds 6,435 shares of common stock directly and 8,948 shares indirectly through his spouse. He also reports multiple option awards over common stock, including grants covering 12,500 shares at an exercise price of $1.50 per share and 5,000 shares at $1.65 per share, with expiration dates running from 2033 to 2035. These positions show his existing equity and option exposure rather than new market transactions.
OKYO Pharma Ltd director John P. Brancaccio has filed an initial ownership report showing his equity position in the company. He directly holds 30,201 shares of common stock, plus multiple option awards over OKYO common shares with exercise prices between $1.46 and $2.13 per share and expirations ranging from 2033 to 2035. These options vest in staggered annual tranches from 2024 through 2029, giving him long‑term, option-based exposure in addition to his current shareholdings.
OKYO Pharma Ltd’s chief financial officer, Keeren Rameshchandra Shah, reports his existing equity stake in the company. He holds 16,667 shares of common stock directly. The filing also lists multiple option awards over common stock, including grants for 31,250 shares at a 1.50 exercise price expiring in 2035 and 25,193 shares at a 2.13 exercise price expiring in 2033.
OKYO Pharma Ltd filed a Form 3 showing that Chief Executive Officer Robert John Dempsey holds four stock option positions over its common stock. Each option position relates to 400,000 shares of common stock at an exercise price of $2.2300 per share.
The options have staggered exercise dates on January 2, 2027, January 2, 2028, January 2, 2029, and January 2, 2030, and all are scheduled to expire on January 2, 2036. The filing records these as existing holdings rather than new market transactions.
OKYO Pharma filed a report highlighting the expansion of its Scientific Advisory Board with the appointment of ophthalmology expert Marta Sacchetti, MD, PhD. She brings extensive experience in corneal and ocular surface diseases and prior leadership as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici.
The filing reiterates the company’s focus on neuropathic corneal pain (NCP) and inflammatory eye diseases, centered on its investigational drug Urcosimod. Urcosimod is the first therapy to receive an IND specifically for NCP and has Fast Track designation from the U.S. FDA. OKYO notes positive pain-reduction data from a randomized, placebo-controlled, double-masked Phase 2 NCP trial involving 18 patients, and prior statistical significance in multiple endpoints in a 240‑patient Phase 2 dry eye disease study. The company recently completed a Phase 2 NCP trial and plans a 150‑patient Phase 2b/3 multiple-dose study of Urcosimod for NCP in the first half of the year.
OKYO Pharma Ltd amendment to a Schedule 13G/A states that Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen each report 0% beneficial ownership of Ordinary Shares as of the close of business on 03/31/2026. The filing lists the reporting persons' business address and CUSIP G6724L116.
OKYO Pharma LTD disclosure: Woodline Partners LP reports beneficial ownership of 3,652,190 shares of Ordinary Shares, representing 7.0% of the class based on an aggregate of 52,479,257 Ordinary Shares described in the filing. The shares are held on behalf of the Woodline Fund.
The filing states Woodline has sole voting and sole dispositive power over the 3,652,190 shares. The disclosure is formatted as a Schedule 13G beneficial-ownership statement and is signed by the reporting person’s GC and CCO.
OKYO Pharma Ltd Schedule 13G: Sirenia Capital Management and Alex Silverstein report joint beneficial ownership of 4,054,054 Ordinary Shares, representing 7.7% of the class. The filing bases the percentage on 52,479,257 Ordinary Shares outstanding as calculated from issuer disclosures.
The filing states the Sirenia Fund holds the shares and has the right to receive dividends or proceeds on more than 5% of the class. Ownership is reported as shared voting and dispositive power of 4,054,054 shares.
OKYO Pharma is highlighting its eye disease program through upcoming scientific meetings and recent clinical data. The CEO will present at Eyecelerator on May 1, 2026, and the Chief Scientific Officer will present Phase 2 data at the ARVO Annual Meeting in Denver in early May.
The company’s lead drug, urcosimod, is an investigational therapy for neuropathic corneal pain (NCP) and inflammatory eye diseases. It is the first therapy to receive an IND specifically for NCP and has Fast Track designation from the U.S. FDA. OKYO reports clinically meaningful pain reduction and quality-of-life improvement in an 18-patient randomized, placebo-controlled, double-masked Phase 2 NCP trial, and statistically significant results in an earlier 240-patient Phase 2 dry eye disease trial. OKYO plans to start a 150-patient Phase 2b/3 multiple-dose NCP study in the first half of the year.
OKYO Pharma is highlighting progress for its lead eye therapy, urcosimod, around the 2026 ASCRS meeting in Washington, DC. The company will convene a Scientific Advisory Board of leading ophthalmology experts to review Phase 2 clinical data and guide the next clinical program.
In parallel, principal investigator Dr. Pedram Hamrah will present Phase 2 proof-of-concept results on urcosimod in neuropathic corneal pain, covering efficacy and safety. Urcosimod holds an IND and FDA Fast Track designation for this indication, and OKYO plans a 150-patient Phase 2b/3 multiple-dose study in the first half of 2026.